Navigation Links
Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients
Date:11/10/2011

ORLANDO, Fla., Nov. 10, 2011 /PRNewswire/ -- Theravalues, a Japan based bio-venture, announced today that Theracurmin™, its curcumin-based product, impacts positively on the prevention of heart failure and its progression for the first time in history. During the human clinical trial started with the registration in July 2010, conducted by the company with National Hospital Organization Kyoto Medical Center and University of Shizuoka, Japan, the researchers found that Theracurmin™, which is absorbed by the body at a rate 27 times higher than curcumin powder, could effectively prevent diastolic failure.

(Logo:  http://photos.prnewswire.com/prnh/20111110/FL04434LOGO)

Dr. Tatsuya Morimoto, Professor at the Division of Molecular Medicine School of Pharmaceutical Sciences, at the University of Shizuoka said, "We are extremely excited to discover that Theracurmin™ has positive effects in curbing left ventricular diastolic failure at a statistically significant level." In the 24-week human trial, Theracurmin™, the absorption-enhanced curcumin invented by Theravalues, was prescribed for 30 subjects with left ventricular diastolic failure and their symptoms improved significantly. "The result of the study encourages patients and the elderly who have been suffering chronic cardiac problems," he added.

Curcumin, a polyphenol derived from turmeric (Curcuma Longa L,) has anti-inflammatory and anti-oxidant therapeutic properties. These properties effectively treat chronic inflammatory diseases. However, it has poor bioavailability due to its low oral absorption. Through Theracurmin™, Theravalues invented an innovative technology to solve this problem by creating surface controlled colloidal dispersion.

The FDA has approved Theracurmin™ for clinical trial in the United States. Last month, The University of Texas MD Anderson Cancer Center began treatment of malignant tumors caused by progressive cancer with Theracurmin™.

Mr. Hashimoto, the Representative Director and President of Theravalues said, "Theracurmin™ brings several exciting avenues of opportunity. We are confident about the potential power of Theracurmin™ not only for heart failure, but also for many incurable diseases and the maintenance of wellness of the people around the globe."

"While we were fascinated by the versatility of curcumin to help treat many diseases, its low oral absorption was the greatest challenge. Theracurmin™ improved the absorption of curcumin, making it 27 times higher than curcumin powder," said Dr. Koji Hasegawa, Director of the Division of Translational Research at National Hospital Organization Kyoto Medical Center. "In addition to its effectiveness on diastolic failure, we have been studying other application of Theracurmin™ to broaden its application into cancers, hepatic functions, skin conditions, ALS and Alzheimer's disease," he continued.

ABOUT THERAVALUES CORPORATION

Founded in 2007, Japan-based Theravalues Corporation strives to deliver better physical and mental health which gives much satisfaction to people around the world. Theravalues creates value through innovation, developing foods, medicines and technological models that achieve high satisfaction and healthy lives.

Learn more at www.theravalues.com/english  

Contact: Masami Hasegawa (Theravalues, Japan)
+81.3.3234.7677
mhasegawa@theravalues.com


'/>"/>
SOURCE Theravalues Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
3. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
4. Mylan Confirms Four First-to-File Challenges
5. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
6. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
7. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
8. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
11. Analysis confirms that nano-related research has strong multidisciplinary roots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... manufacturers to re-engineer their control technology again and again. METTLER TOLEDO has released ... machine manufacturers. The videos illustrate how integration of the ACT350 into Siemens and ...
(Date:5/21/2017)... ... 19, 2017 , ... Ovation Fertility scientists’ work is being ... Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and Saturday (May ... excellence in clinical laboratory services and regulations. , “We are pleased to ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... 28, 2017 at the Prince Of Wales Private Hospital. The procedure was performed ... C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The AxioMed ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... with psychonneuroendocrine stress expertise, and further enhances its scientific power by providing ... A. Granger, Ph.D., has agreed to join the scientific advisory board. “We ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):